Omeros Stock Gains 52% On Successful Trial Results

Dow Jones12-19

By Katherine Hamilton

Omeros shares gained Thursday after the company shared positive results for a trial of its treatment of a stem-cell transplantation complication.

The stock rose 52% to $11.15. It has nearly doubled over the past month and a half after reporting third-quarter earnings in mid-November.

The Seattle-based biopharmaceutical company said its narsoplimab treatment met its primary endpoint in a trial.

Narsoplimab is a monoclonal antibody designed to treat a complication in stem-cell transplantation called hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

The trial compared the survival rate of 28 patients with more than 100 patients in a control group who did not receive narsoplimab. Patients receiving the treatment showed significantly better survival rates.

Omeros plans to resubmit a biologics license application for its narsoplimab to the Food and Drug Administration as soon as possible, it said. If approved, narsoplimab would be the first approved treatment for TA-TMA, Omeros said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 19, 2024 10:56 ET (15:56 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492079170?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 23:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492079170","market":"nz","top_or_hot":-1,"title":"Omeros Stock Gains 52% On Successful Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Omeros shares gained Thursday after the company shared positive results for a trial of its treatment of a stem-cell transplantation complication. \n</p>\n<p>\n  The stock rose 52% to $11.15. It has nearly doubled over the past month and a half after reporting third-quarter earnings in mid-November. \n</p>\n<p>\n  The Seattle-based biopharmaceutical company said its narsoplimab treatment met its primary endpoint in a trial. \n</p>\n<p>\n  Narsoplimab is a monoclonal antibody designed to treat a complication in stem-cell transplantation called hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). \n</p>\n<p>\n  The trial compared the survival rate of 28 patients with more than 100 patients in a control group who did not receive narsoplimab. Patients receiving the treatment showed significantly better survival rates. \n</p>\n<p>\n  Omeros plans to resubmit a biologics license application for its narsoplimab to the Food and Drug Administration as soon as possible, it said. If approved, narsoplimab would be the first approved treatment for TA-TMA, Omeros said. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 19, 2024 10:56 ET (15:56 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omeros Stock Gains 52% On Successful Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmeros Stock Gains 52% On Successful Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 23:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Katherine Hamilton \n\n\n  Omeros shares gained Thursday after the company shared positive results for a trial of its treatment of a stem-cell transplantation complication. \n\n\n  The stock rose 52% to ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6512","symbol_name":"房地产股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492079170","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492079170","pubTimestamp":1734623760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Omeros shares gained Thursday after the company shared positive results for a trial of its treatment of a stem-cell transplantation complication.The stock rose 52% to $11.15. It has nearly doubled over the past month and a half after reporting third-quarter earnings in mid-November.The Seattle-based biopharmaceutical company said its narsoplimab treatment met its primary endpoint in a trial.Narsoplimab is a monoclonal antibody designed to treat a complication in stem-cell transplantation called hematopoietic stem cell transplant-associated thrombotic microangiopathy .The trial compared the survival rate of 28 patients with more than 100 patients in a control group who did not receive narsoplimab. Patients receiving the treatment showed significantly better survival rates.Omeros plans to resubmit a biologics license application for its narsoplimab to the Food and Drug Administration as soon as possible, it said. If approved, narsoplimab would be the first approved treatment for TA-TMA, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6512":"房地产股","OMER":"奥麦罗制药","PA3.SI":"长益","BK4007":"制药","BK6045":"建筑与工程"},"translate_title":"Omeros股价因试验结果成功而上涨52%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":1,"PA3.SI":0.65},"content_text":"By Katherine Hamilton \n\n\n  Omeros shares gained Thursday after the company shared positive results for a trial of its treatment of a stem-cell transplantation complication. \n\n\n  The stock rose 52% to $11.15. It has nearly doubled over the past month and a half after reporting third-quarter earnings in mid-November. \n\n\n  The Seattle-based biopharmaceutical company said its narsoplimab treatment met its primary endpoint in a trial. \n\n\n  Narsoplimab is a monoclonal antibody designed to treat a complication in stem-cell transplantation called hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). \n\n\n  The trial compared the survival rate of 28 patients with more than 100 patients in a control group who did not receive narsoplimab. Patients receiving the treatment showed significantly better survival rates. \n\n\n  Omeros plans to resubmit a biologics license application for its narsoplimab to the Food and Drug Administration as soon as possible, it said. If approved, narsoplimab would be the first approved treatment for TA-TMA, Omeros said. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 10:56 ET (15:56 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492079170"}